Marco Meglio

Nearly all patients in this cohort achieved a clinically meaningful >3-point increase during the study period, demonstrating a consistent response to the gene therapy.

No unexpected safety signals were reported in the post hoc analysis.

After meeting co-primary end points of pain freedom and freedom from the most bothersome symptom, the acute migraine agent has been cleared for a phase 3 trial by the FDA.

Eligible patients with Duchenne muscular dystrophy may receive the drug while it is under priority review by the FDA.

Patients with multiple sclerosis who reported cannabis use noted that it was helpful in relieving pain, as well as other symptoms, such as sleep, depression, anxiety, and/or stress.

The risk of relapse was higher with treatment of mycophenolate mofetil in patients with neuromyelitis optica spectrum disorder and other first-line immunosuppressants, compared to treatment with rituximab.

Eton Pharmaceuticals plans to submit a new drug application for ET-101 in the third quarter of 2020, anticipating its formulation to be the first approved oral topiramate solution.

A combination of different physical therapy interventions designed to improve fitness, motor function, and gait are all recommended when guiding clinical practice for patients with Huntington disease.

The ongoing phase 3 trial of the Biohaven drug is expected to be completed October 20, 2021.

Statistically significant associations between stress-related disorders were identified in those with Alzheimer disease, but not with Parkinson disease or amyotrophic lateral sclerosis.

Patients opted for nontriptan acute medications such as opioids and nonsteroidal anti-inflammatory drugs instead of staying on triptans at 12- and 24-month follow-ups.

Further results of the SPI2 trial will be presented at the upcoming American Academy of Neurology 2020 Annual Meeting in Toronto.

The label expansion now allows patients who require non-brain MRI monitoring to receive treatment with the stimulation device.

Despite the introduction of second-generation ASMs, drug tolerability has been relatively unchanged over the last 30 years.

The drug’s Prescription Drug User Fee Act date is set for October 20, 2020.

Compared with intensive care units or normal wards, stroke units were associated with reduced mortality in patients with intracranial hemorrhage.

Patients with relapsing multiple sclerosis showed declining scores on tests of cognitive processing speeds from baseline to 3-month follow-up post-relapse.

The chief executive officer of Clene Nanomedicine discussed CNM-Au8, their novel investigational drug that will be used in the world’s first platform trial of potential ALS treatments.

Both the 10- and 20-mg doses were associated with clinically relevant reductions in convulsive seizures with a favorable safety and tolerability profile.

Similar effects were observed for each proxy SMPS component when compared with placebo.

When performed by itself, endovascular therapy had greater rates of intracranial hemorrhage compared to a combination of both endovascular therapy and intravenous thrombolysis.

The drug was previously approved for the treatment of acute repetitive seizures and granted 7 years of orphan drug exclusivity in January 2020.

Gaboxadol is the first treatment in 50 years associated with positive change in outcomes in Angelman syndrome.

Neurology News Network for the week ending February 29, 2020.

The president and founder of Cure Rare Disease discussed the company’s custom therapeutics for patients with rare diseases, including the use of CRISPR gene-editing technology to develop treatments for Duchenne muscular dystrophy.

Compared with patients who initially received interferon treatment, those given ocrelizumab had superior disability progression after a 6-year follow-up.

Patients with a disease duration of <16 years demonstrated a significantly greater reduction in risk for confirmed disability progression (CDP) at 3 and 6 months.

The orally administered tyrosine kinase inhibitor was shown to delay disability progression in patients with primary progressive multiple sclerosis.

Stroke patients experienced higher rates of thrombolysis as well as faster alarm to treatment times when mobile stroke units were present.

Retrotope had already received FDA approval to test RT001, a chemically modified polyunsaturated fatty acid agent, in expanded access trials of 3 patients with progressive supranuclear palsy.